ICLR - ICON Public Limited Company
| Previous Close | 145.09 |
| Open | 144.89 |
| Bid | 147.58 x 4000 |
| Ask | 147.74 x 1200 |
| Day's Range | 143.01 - 147.95 |
| 52 Week Range | 118.10 - 155.33 |
| Volume | 130,938 |
| Avg. Volume | 254,410 |
| Market Cap | 7.964B |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | 24.19 |
| EPS (TTM) | 6.10 |
| Earnings Date | Jul 23, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 156.54 |
- Zacks•14 hours ago
Teladoc (TDOC) Up 22% in a Year: Will the Rally Continue?
Teladoc's increasing visits and subscriptions are likely to aid revenue growth. This will further drive its share price.
- Markit•2 days ago
See what the IHS Markit Score report has to say about ICON PLC.
ICON PLC NASDAQ/NGS:ICLRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ICLR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ICLR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $38 million over the last one-month into ETFs that hold ICLR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey•7 days ago
Hedge Funds Have Never Been More Bullish On ICON Public Limited Company (ICLR)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
- Simply Wall St.•15 days ago
ICON Public Limited Company (NASDAQ:ICLR): Financial Strength Analysis
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as ICON Public Limited...
- Zacks•15 days ago
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
- Business Wire•28 days ago
ICON’s Acquisition of MeDiNova Research
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a majority shareholding in MeDiNova Research, a site network with research sites in key markets in Europe and Africa, and that it has the right to acquire the remaining shares in the company by Quarter 3 2020. The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ICLR earnings conference call or presentation 2-May-19 2:00pm GMT
Q1 2019 ICON PLC Earnings Call
- Simply Wall St.•last month
Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Business Wire•last month
ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has been awarded the Clinical Research Team of the Year (with Eli Lilly and Company), for the second consecutive year, and Best in Health Economics and Outcomes Research (with Bristol-Myers Squibb and LATITUDE, powered by AXON). The awards indicated are ICON’s third win for Clinical Research Team of the Year since the inaugural CARE Awards in 2016, and first win in the Best Health Economics and Outcomes Research category. ICON and Eli Lilly and Company won the award for the successful execution of a full-service Cardiovascular Outcomes Trial (CVOT), in which they were able to achieve exceptional patient retention despite early challenges.
- Business Wire•last month
ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the release of its web based patient engagement platform, to provide patients with study specific information and connectivity with the nearest investigative site. The solution supplements patient recruitment outreach by sites and increases visibility of potential study participants for sponsors and sites. Patient recruitment specialists work with sponsors to develop outreach programs that incorporate the right mix of digital channels, traditional methods and patient advocacy partnerships to attract patients to a study branded website hosted on the platform.
Motley Fool•2 months agoICON (ICLR) Q1 2019 Earnings Call Transcript
ICLR earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.88% and 0.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Icon PLC: 1Q Earnings Snapshot
The Dublin-based company said it had profit of $1.63 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings ...
- Zacks•2 months ago
Icon PLC (ICLR) Reports Next Week: Wall Street Expects Earnings Growth
Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
ICLR or HQY: Which Is the Better Value Stock Right Now?
ICLR vs. HQY: Which Stock Is the Better Value Option?
- Insider Monkey•2 months ago
Do Hedge Funds Love ICON Public Limited Company (ICLR)?
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Simply Wall St.•2 months ago
Shareholders Are Thrilled That The ICON (NASDAQ:ICLR) Share Price Increased 213%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over 100%. For instance, t...
- Business Wire•4 months ago
ICON Wins Multiple Categories in 2019 CRO Leadership Awards
ICON plc, (ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several categories in the annual CRO Leadership Awards. ICON received 2019 CRO Leadership Awards in five categories, each further divided into three groups – Big Pharma, Small Pharma, and Overall.
- GlobeNewswire•4 months ago
Report: Developing Opportunities within Amazon, Prospect Capital, Alliance Data, Duke Realty, Stellus Capital Investment, and ICON — Future Expectations, Projections Moving into 2019
NEW YORK, Feb. 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
